特集／関節リウマチ治療における分子標的薬の進歩
4．細胞内分子標的薬：JAK 阻害薬および Syk 阻害薬
2013 年 44 巻 1 号 p. 23-27
詳細
2013 年 44 巻 1 号 p. 23-27
Biologics targeting TNF-α and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologics on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologics. Here we overview the development process of these inhibitors together with the results of clinical trials. (Jpn J Clin Pharmacol Ther 2013; 44(1): 23-27)
